Author

J. Tami

Observed names: J A Tami, J Tami, JOSEPH TAMI, Joseph Tami

Institution: Ionis Pharmaceuticals (United States)

Observed institutions: Inserm, The University of Texas at San Antonio Health Science Center, Ionis Pharmaceuticals (United States), The University of Texas at San Antonio

OpenAlex ID: A5111508887

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

2002 · B R Yacyshyn, W Y Chey, et al. · Gut · 221

Dose ranging pharmacokinetic trial of high‐dose alicaforsen (intercellular adhesion molecule‐1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease

2002 · B. R. Yacyshyn, C. Barish, et al. · Alimentary Pharmacology & Therapeutics · 70

T cell hybridomas reactive with the acetylcholine receptor and its subunits.

1987 · J A Tami, O E Urso, et al. · The Journal of Immunology · 18

Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1

2005 · B R Yacyshyn, A Schievella, et al. · Clinical & Experimental Immunology · 8

Evidence against chronic antigen-specific T lymphocyte activation in myasthenia gravis

1996 · A.J. Infante, P.D. Infante, et al. · Journal of Neuroscience Research · 7

Clinical Applications of Filgrastim and Stem Cell Factor In Vivo and In Vitro

1994 · GEORGE MORSTYN, JOHN GLASPY, et al. · Journal of Hematotherapy · 5

Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia

2026 · Ali Taher, Michael D Diamantidis, et al. · Blood Advances · 4

Sefety of retreatment with antisense to icam-1 (isis 2302) in patients with steroid-dependent Crohn's disease

1998 · B.R. Yacyshyn, M.B. Bowen-Yacyshyn, et al. · Gastroenterology · 1

Effect of APOC3 inhibition with volanesorsen on hepatic steatosis in patients with severe hypertriglyceridemia

2023 · T. Prohaska, V. Alexander, et al. · Atherosclerosis

Natural temporal variability in Lp(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx antisense oligonucleotide clinical trials

2016 · N.J. Viney, S. Marcovina, et al. · Atherosclerosis

Prevalence of LPA single nucleotide polymorphisms and isoforms in patients enrolled in a phase 2 IONIS-APO(a)Rx clinical trial

2016 · E.S. Stroes, F.M. van der Valk, et al. · Atherosclerosis

Antisense to ICAM-1 affects the peripheral blood expression and intestinal expression of adhesion molecules in Crohn's disease

1998 · M.B. Bowen-Yacyshyn, W. Shanahan, et al. · Gastroenterology

Recombinant interleukin-2 and the quest for FDA approval.

1991 · J A Tami · PubMed

Works count: 13

Citation count: 334

H-index: 5

I10-index: 3